Key Highlights

  • Beyond Air said its first-generation LungFit PH system is generating commercial momentum.
  • A second-generation system is designed with a smaller footprint, lower weight and simpler operation.
  • A PMA supplement would expand FDA labeling to permit use during air and ground patient transport.
  • The company said discussions with the FDA are active, but no approval date was given.

Beyond Air, Inc. (NASDAQ:XAIR), a commercial-stage medical device and biopharmaceutical company focused on nitric oxide therapy, reported financial results for the quarter ended September 30, 2026. The company said its first-generation LungFit PH system is building commercial momentum and that a second-generation system could expand its market, subject to FDA approval. The November 11, 2026 update pairs quarterly results with a regulatory process that is still open. Inhaled nitric oxide therapies are used in settings where patients need pulmonary support, and device design affects how hospitals and transport services can use them.

The Current LungFit PH Business

The company said its US pipeline is expanding, with rising Demand for the first-generation system, new account wins and steady renewal rates. It linked customer satisfaction to its technology and its operational efficiencies, and said those factors could carry over to a second-generation launch.

The update does not provide system placements, unit counts or Revenue for the first-generation product, so the scale of demand cannot be measured from the material reviewed.

Devices used for patient transport must be compact and simple to operate, since space and staffing are limited in ambulances and aircraft. The design goals the company lists, including reduced weight and simpler operation, are aimed at those constraints.

What the Second-Generation System Offers

The planned system is designed to have a smaller footprint, reduced weight, simplified operation, longer service intervals and expanded operational flexibility. The company presents these as potential advantages over the current model.

The PMA supplement the company is seeking would expand FDA labeling to permit use during patient transport by air and ground. If approved, that label would widen the settings where the system could be used.

Longer service intervals reduce the maintenance burden for hospitals and service providers. That feature can be a Factor in purchasing decisions, although the update does not quantify the difference from the current system.

Regulatory Progress and Timing

Management said the company is in active and productive discussions with the FDA and is making progress on the remaining steps of the review. The update does not give a decision date, so the commercial timing for the second-generation system remains uncertain.

Without a set timetable, the company's revenue plans for the new system cannot be dated with confidence. The outcome of the review could also narrow the label the company receives.

Regulatory supplements that expand labeling can take considerable time, and the outcome may differ from what the company seeks. Approval of a narrower label would limit the use cases the company can market.

Financial Position and Risks

The sections of the update reviewed do not provide the quarter's cash balance or loss figures, so the company's funding position cannot be assessed here. Regulatory review carries the risk that approval is delayed, narrowed or not granted, and the expansion the company describes depends on that outcome.

Investors will track the FDA timetable, first-generation placements and any financing needs that arise before the second-generation product launches.

Investors would need the cash balance, loss figures and Placement numbers to judge the company's financial exposure while it awaits the FDA decision. Those figures are not in the sections of the update reviewed.

Final Word

Beyond Air is linking its commercial growth to a second-generation system whose expanded labeling still requires FDA action. The update points to progress in discussions but gives no approval date, so the market expansion it describes remains subject to the regulatory outcome. Later filings will show whether demand for the current system carries into the planned next launch. The regulatory outcome will determine whether the second-generation system widens the company's market as planned.